The Filing Desk

Oramed Pharmaceuticals

ORMP · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

ORMP · Last close · November 19, 2026
$3.69
Value Oramed Pharmaceuticals yourself

Oramed Pharmaceuticals reported revenue of $2 million in fiscal 2025. Its operating margin was −754.4%. Free cash flow was −$9 million. It paid out $5 million in dividends and buybacks. The diluted share count rose 3.8%.

ORAMED PHARMACEUTICALS INC. Latest fiscal year ended December 31, 2025 10-K filed March 26, 2026 · 0001213900-26-034835 Updated
Revenue
$2M
 
Operating margin
−754.4%
 
Net income
$64M
 
Free cash flow
−$9M
 
Return on equity
37.0%
49.3 pts
Market cap
$159M
Nov 19 close
P/E
1.1x
On $3.42 EPS, 4 qtrs

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

About these figures. Diluted earnings per share for fiscal 2016 to 2019 is left blank: the SEC's structured data gives it the opposite sign from net income per share. Interest coverage for fiscal 2025 is blank: the 10-K's structured data has no interest expense for that year.

Charts show fiscal years, from the 10-K filings.

What Oramed Pharmaceuticals does

Oramed is a pharmaceutical company that researches ways to take proteins by mouth instead of by injection. Its technology is a pill form designed to survive the harsh conditions of the digestive tract and deliver active insulin or other proteins without changing them. It has no approved products.

It plans to begin, in the second half of 2026, a US clinical trial of its oral insulin in a defined group of patients, a trial that would be run by OraTech, a joint venture it formed in 2024 with Hefei Tianhui Biotech. The 10-K says the initial closing of an amended joint venture did not occur because its partner did not meet the closing conditions, and that Oramed gave notice of termination of that agreement on October 23, 2025.

Besides its drug work, Oramed invests in healthcare and life sciences companies, and it holds notes and warrants tied to Scilex Holding Company from a 2023 transaction. It says it reviews its pipeline and looks at strategic opportunities, and its filing refers to a strategic review process.

Its biggest risks, as it describes them

  • Its strategic review may not succeed or finish on time.
  • It has a history of losses and may not be profitable.
  • Its oral insulin trials may be delayed or fail, and the company has limited experience running trials.
  • It may not get regulatory approval for its products.
  • It may not earn a return on the investments and securities it holds.
From Oramed Pharmaceuticals's annual report on Form 10-K, filed March 26, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

From fiscal 2023 to 2025, earnings per share grew 227.3% a year and net income 254.2% a year, as new shares raised the share count by 4% and diluted each share's earnings.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red. Where the filings' structured data doesn't give a year's earnings per share, the column is blank.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments8344675851
Debt incl. finance leases—0———
Net debt (negative means net cash)—−44———
Net debt to EBITDA—————
Debt to equity—0.0x———
Interest coverage——−7.7x−15.0x—
Current ratio14.3x27.3x3.1x25.2x7.0x
Quick ratio14.3x27.3x3.1x25.2x7.0x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Oramed Pharmaceuticals' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought Oramed Pharmaceuticals shares on the open market, and 2 insiders sold $941,874, all of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Jul 1, 2026Joshua HexterCOO & CboSold plan137,000$4.46$611,020Form 4
Jul 1, 2026Avraham GabayChief Financial OfficerSold plan73,360$4.51$330,854Form 4
Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 40−837.7%——
Altman Z''3.4116.927.80
Accruals ratio8.1%−5.7%37.9%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positivePassFailPass
Cash from operations is positiveFailFailFail
Return on assets rosePassFailPass
Cash from operations exceeds net incomeFailPassFail
Debt fell relative to assets———
Current ratio roseFailPassFail
Share count didn't riseFailFailFail
Gross margin rose———
Revenue rose relative to assetsFail——
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put Oramed Pharmaceuticals side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Oramed PharmaceuticalsFY25—−754.4%−457.7%———
Dianthus TherapeuticsFY25−67.3%−8,739.3%−6,349.4%———Compare
LipocineFY25−82.3%−524.7%————Compare
GeoVax LabsFY25−37.1%−869.3%−863.8%——2Compare
Rani TherapeuticsFY2558.9%−2,346.0%−1,151.4%−127.1%—4Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue12233331—2
Revenue growth—283.1%−0.3%10.4%0.3%−0.3%0.0%−50.4%——
Gross profit0223—————0
Research and development8101214102128966
Operating income−10−11−14−15−12−24−41−16−13−15
Net income−11−10−13−14−12−23−375−1964
Diluted EPS (US$)————0.560.78−0.940.14−0.481.50
Diluted shares (millions)13131518202839414142
Cash flow
Cash from operations5−6−15−13−12−21−28−10−8−9
Capital expenditure0000000000
Free cash flow5−6−15−13−13−22−28−11−8−9
Dividends paid0000000000
Share buybacks0000000025
Acquisitions0000000000
Stock-based compensation12210312446
Balance sheet at fiscal year end
Cash and short-term investments77107238344675851
Debt incl. finance leases——1412——0———
Total assets4339473545128162221155231
Total liabilities17201615121210581031
Shareholders' equity2619311933116152164146200
Margins and ratios
Gross margin23.6%92.4%103.5%96.7%—————0.7%
Operating margin−1,561.6%−438.6%−552.4%−541.3%−433.8%−896.1%−1,502.0%−1,176.8%—−754.4%
Net margin−1,710.5%−426.7%−519.7%−531.1%−424.8%−850.5%−1,352.6%379.7%—3,202.5%
Free cash flow margin724.8%−237.7%−598.7%−479.3%−462.1%−797.5%−1,051.2%−787.2%—−457.7%
Rule of 40 (growth + FCF margin)—45.5%−599.0%−468.9%−461.8%−797.7%−1,051.2%−837.7%——
Return on capital———−38.5%——————
Return on equity−43.0%−46.1%−50.5%−56.9%−44.0%−30.9%−27.3%3.2%−12.3%37.0%
Return on assets−31.7%−25.7%−29.6%−35.0%−29.0%−26.6%−25.2%2.7%−10.1%33.2%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Oramed Pharmaceuticals' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Oramed Pharmaceuticals.